ChronoScale Corporation Common Stock (NASDAQ:CHRN) Stock Price Down 8.3% – Time to Sell?

ChronoScale Corporation Common Stock (NASDAQ:CHRN) shares were down 8.3% on Thursday. The company traded as low as $14.99 and last traded at $15.61. Approximately 144,336 shares were traded during trading, a decline of 35% from the average session volume of 223,432 shares. The stock had previously closed at $17.02.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CHRN. Northland Securities began coverage on ChronoScale Corporation Common Stock in a research report on Friday, September 18th. They set an “outperform” rating and a $32.00 target price for the company. Compass Point started coverage on ChronoScale Corporation Common Stock in a research note on Friday, October 16th. They set a “buy” rating and a $25.00 price target on the stock. Finally, Weiss Ratings downgraded ChronoScale Corporation Common Stock from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, October 23rd. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, ChronoScale Corporation Common Stock currently has a consensus rating of “Hold” and a consensus price target of $21.00.

ChronoScale Corporation Common Stock Stock Performance

The company has a market cap of $2.27 billion, a P/E ratio of -3.61 and a beta of 0.98. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.30 and a quick ratio of 0.30. The business has a 50-day moving average of $18.97 and a two-hundred day moving average of $15.90.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last released its quarterly earnings results on Wednesday, October 14th. The company reported ($0.29) earnings per share for the quarter. The firm had revenue of $41.48 million during the quarter. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 66.16%. On average, sell-side analysts predict that ChronoScale Corporation Common Stock will post -0.49 EPS for the current fiscal year.

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.